ArticleFrontiers in neuroscience2026
Predictive value of blood composite biomarkers for hemorrhagic transformation following mechanical thrombectomy in acute anterior circulation large vessel occlusion stroke patients.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hemorrhagic transformation (HT) is a devastating complication of mechanical thrombectomy (MT) for acute anterior circulation large vessel occlusion (LVO), yet reliable early prediction tools remain limited. This study systematically compared nine blood composite biomarkers to identify the optimal metabolic-immune integrative predictor of HT. Methods: A total of 206 patients with acute anterior circulation LVO who underwent MT were retrospectively enrolled. Nine composite biomarkers were calculated from routine admission laboratory tests: platelet-to-lymphocyte ratio (PLR), neutrophil-to-platelet ratio (NPR), systemic inflammation response index (SIRI), pan-immune inflammation value (PIV), monocyte-to-HDL ratio (MHR), neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), glucose-to-potassium ratio (GPR), and glucose-to-lymphocyte ratio (GLR). A stratified screening strategy was employed: elastic net regression for baseline variable selection, Spearman correlation for biomarker clustering, and univariate AUC with DeLong test for representative selection. Model evaluation incorporated discrimination (AUC with DeLong test and Bootstrap 1,000-iteration optimism correction), calibration (Hosmer-Lemeshow test and Brier score), and clinical net benefit (NRI, IDI, and decision curve analysis). Results: HT occurred in 53 patients (25.7%). Elastic net regression identified six baseline variables: mean platelet volume, blood glucose, D-dimer, history of alcohol consumption, leukoaraiosis, and pulmonary infection. Spearman clustering yielded five representative biomarkers: GLR, SIRI, GPR, NPR, and MHR. Among these, GLR was the only biomarker that showed a trend toward improving? the baseline model's discrimination (AUC: 0.852-0.882; △AUC = 0.030), although this difference did not reach statistical significance ( Conclusion: Among nine composite biomarkers, GLR provides the greatest incremental predictive value for HT following MT in acute anterior circulation LVO patients. As a routinely accessible metabolic-immune integrative index, GLR may serve as an early warning layer for perioperative risk stratification, though integration with imaging and procedural information remains essential for clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.